Abstract
Effective treatments remain insufficient for conditions such as cancer, autoimmune diseases, infections, and neurological disorders, resulting in numerous unmet medical needs that require new drug development. On the other hand, antibody therapeutics, known as “magic bullets” for their ability to identify and act on target cells or proteins precisely, have contributed to overcoming these challenges. Additionally, advancements are being made in next-generation antibody therapeutics, including Antibody-drug conjugates（ADCs）, Radioimmunotherapy, and Bispecific antibodies（including T cell engagers） that can recognize two targets simultaneously. These developments are expected to provide new modalities for areas with low treatment satisfaction and efficacy, improving future patient quality of life（QOL）. therapeutic effectiveness was previously low, offering hope for improved quality of life.
